Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a β-cell line, MIN6 cells
M Ishikawa, F Okajima, N Inoue… - … of atherosclerosis and …, 2006 - jstage.jst.go.jp
M Ishikawa, F Okajima, N Inoue, K Motomura, T Kato, A Takahashi, S Oikawa, N Yamada…
Journal of atherosclerosis and thrombosis, 2006•jstage.jst.go.jpStatins are specific and potent competitive inhibitors of 3-hydroxy-3methylglutaryl coenzyme
A (HMG-CoA) reductase and are widely used as plasma cholesterol-lowering drugs to
prevent the development and progression of atherosclerosis. Evidence for reduction of the
incidence of cardiovascular diseases by statins has now been fully established1-6).
Diabetes is a major risk for cardiovascular diseases, and statins are also used for patients
with diabetes7, 8); however, the effects
A (HMG-CoA) reductase and are widely used as plasma cholesterol-lowering drugs to
prevent the development and progression of atherosclerosis. Evidence for reduction of the
incidence of cardiovascular diseases by statins has now been fully established1-6).
Diabetes is a major risk for cardiovascular diseases, and statins are also used for patients
with diabetes7, 8); however, the effects
Statins are specific and potent competitive inhibitors of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase and are widely used as plasma cholesterol-lowering drugs to prevent the development and progression of atherosclerosis. Evidence for reduction of the incidence of cardiovascular diseases by statins has now been fully established1-6). Diabetes is a major risk for cardiovascular diseases, and statins are also used for patients with diabetes7, 8); however, the effects
jstage.jst.go.jp